We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
NSCLC Therapy Management and Biomarker Testing
Mark Socinski, MD
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Jason J. Luke, MD, FACP
Tara C. Mitchell, MD
Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making
Richard S. Finn, MD
Closing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
Adam DeVore, MD
Lauren Barron, MD
Navin Kapur, MD
Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
Martin Pollak, MD
Susanne Nicholas, MD, MPH, PhD
Optimizing Bone Health in Postmenopausal Post-Fracture Patients
Andrea Singer, MD, FACP, CCD
Susan V. Bukata, MD, FAOA, FAAOS
What Are the Data Supporting Neoadjuvant Therapy in Melanoma?
Jeffrey S. Weber, MD, PhD
Integrating Immune Checkpoint Therapy Into the Management of Resectable Melanoma
Brian Gastman, MD
Michael T. Tetzlaff, MD, PhD
Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?
Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers
Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas
Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?
Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?
What Are the Data Supporting Adjuvant Therapy in Melanoma?
What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education